3 Largecap Pharma Stocks to Watch for Future Multibagger Potential: Sun Pharma, Torrent Pharma and Zydus Lifesciences

Pharma stocks to watch for multibagger potential start with a simple filter: size, a clean financial record and earnings that keep growing. Sun Pharma, Torrent Pharma and Zydus Lifesciences meet that test, with market caps from Rs 1.14 lakh crore to Rs 4.22 lakh crore and Sun Pharma offering the fastest profit growth, 35.75% a year since FY22. India supplies a large share of the world's generic medicines, and large drugmakers are adding specialty products and chronic therapies for higher margins.

This list covers India's largest listed drugmakers with complete, verifiable financials, ranked by market capitalisation. Each company has a market cap above Rs 1 lakh crore. Investors screening pharma stocks usually begin with size and balance sheet strength, and this list follows the same logic. All figures are as of 16 October 2026 and are drawn from NSE and BSE data and company filings.

Click Here – Get Free Investment Predictions

What Are Pharma Stocks and Why Do They Attract Multibagger Interest?

Pharma stocks are listed companies that develop, manufacture and sell medicines, ranging from branded generics in India to generics and specialty products in the United States and other markets. Revenue is spread across therapies, countries and product types.

A growing domestic market for chronic therapies, a shift to specialty medicines and rising export approvals support earnings. Companies with strong research pipelines, clean regulatory records and high returns on equity are the ones investors favour in pharma stocks.

Pharma Stocks at a Glance: Price, Market Cap, PE and ROE

Prices are as of 16 October 2026, mid-session. Zydus Lifesciences has the lowest PE of the group at 24.78, while Torrent Pharma posts the highest return on equity at 25.49%.

Stock	CMP (Rs)	Market Cap (Rs Cr)	PE	Industry PE	ROE	Debt to Equity	52-Week Range (Rs)
Sun Pharmaceutical Industries	1,762.20	4,22,427	34.86	36.42	13.74%	0.06	1,583.70 to 2,046.90
Torrent Pharmaceuticals	4,584.10	1,75,196	81.26	36.42	25.49%	1.79	3,480.60 to 5,250.00
Zydus Lifesciences	1,140.10	1,13,790	24.78	36.42	18.59%	0.46	835.50 to 1,232.10

Sun Pharma: 35.75% Profit CAGR Since FY22

Sun Pharmaceutical Industries is one of India's largest drugmakers and sells generic and specialty medicines in India and overseas. It reported FY26 revenue of Rs 61,673.94 crore, up 12.69% year on year, and net profit of Rs 11,564.52 crore, up 5.32%. Net profit has compounded at 35.75% a year since FY22, while revenue has grown 11.62% a year. Operating margin was 31.47% in FY26. The debt-to-equity ratio is 0.06, which keeps interest costs low.

In the June 2026 quarter, revenue rose 11.93% to Rs 16,023.50 crore and net profit grew 26.41% to Rs 2,910.80 crore. The share price has gained 110.81% over five years. Domestic institutions raised their holding from 20.23% in September 2025 to 22.27% in September 2026. The stock trades at a PE of 34.86 against an industry PE of 36.42, below the sector average, with a return on equity of 13.74%.

Torrent Pharma: 28.79% Profit CAGR Since FY22

Torrent Pharmaceuticals makes branded medicines for chronic therapies such as cardiac, gastro-intestinal and central nervous system care in India and overseas. It reported FY26 revenue of Rs 13,886.15 crore, up 20.34% year on year, and net profit of Rs 2,138.18 crore, up 11.87%. Net profit has compounded at 28.79% a year since FY22, while revenue has grown 12.38% a year. Operating margin was 22.70% in FY26.

The stock trades at a PE of 81.26 against an industry PE of 36.42, with a return on equity of 25.49%. In the June 2026 quarter, revenue rose 56.29% to Rs 4,909 crore and net profit grew 3.28% to Rs 566 crore. The share price has gained 194.63% over five years and 29.72% over the past year. Domestic institutions raised their holding from 9.28% in September 2025 to 12.87% in July 2026.

Zydus Lifesciences: 21.24% Profit CAGR Since FY22

Zydus Lifesciences develops and sells generic medicines, vaccines, consumer wellness products and specialty therapies. It reported FY26 revenue of Rs 27,657.90 crore, up 17.64% year on year, and net profit of Rs 5,026.40 crore, up 8.92%. Net profit has compounded at 21.24% a year since FY22, while revenue has grown 15.89% a year. Operating margin was 16.55% in FY26. The debt-to-equity ratio is 0.46.

Revenue for the June 2026 quarter rose 20.72% to Rs 8,123.10 crore, at an operating margin of 25.86%. The share price has gained 113.38% over five years and 15.79% over the past year. Domestic institutions raised their holding from 10.86% in September 2025 to 11.28% in September 2026. The stock trades at a PE of 24.78 against an industry PE of 36.42, below the sector average, with a return on equity of 18.59%.

Pharma Stocks: Financial Comparison on Growth and Margins

The table compares scale and growth across these pharma stocks. Latest quarter means the most recent reported quarter for each company, and only metrics that are positive for every company are shown.

Stock	Revenue (Rs Cr)	Net Profit (Rs Cr)	Revenue Growth (YoY)	4-Year Revenue CAGR	4-Year Net Profit CAGR	Operating Margin (Latest Quarter)
Sun Pharma	61,673.94	11,564.52	12.69%	11.62%	35.75%	32.52%
Torrent Pharma	13,886.15	2,138.18	20.34%	12.38%	28.79%	33.73%
Zydus Lifesciences	27,657.90	5,026.40	17.64%	15.89%	21.24%	25.86%

Check the Univest Screener for live data on these pharma stocks

Institutional Holding in Sun Pharma, Torrent Pharma and Zydus Lifesciences

Institutional holding shows who is backing these pharma stocks alongside the promoter. The table uses the latest reported quarter for each. Sun Pharma has the deepest institutional backing, with FII and DII together holding 36.63% as of September 2026. Domestic institutions increased their holding over the past year in Sun Pharma (from 20.23% to 22.27%), Torrent Pharma (from 9.28% to 12.87%) and Zydus Lifesciences (from 10.86% to 11.28%).

Stock	Promoter	FII	DII	Public	Quarter
Sun Pharma	52.68%	14.36%	22.27%	10.70%	September 2026
Torrent Pharma	60.78%	17.97%	12.87%	8.38%	July 2026
Zydus Lifesciences	75.01%	7.04%	11.28%	6.66%	September 2026

Risks to Weigh in Pharma Stocks

Being careful with pharma stocks means looking at what can slow the story as well as what can speed it up. Four points matter most:

• Regulatory inspections and approvals can change the timing of product launches and exports.
• Pricing pressure on generics in overseas markets can affect margins in the export business.
• Valuation: Torrent Pharma trades at a PE of 81.26 against an industry PE of 36.42, so earnings need to keep growing to support the price.
• Concentration: Holding all 3 names puts the allocation in one sector, so size each position to match your risk appetite.

How to Choose Between Pharma Stocks

Picking from pharma stocks comes down to four checks, applied in order.

1. Check balance sheet strength first, and prefer a debt-to-equity ratio below 1 for non-financial companies.
2. Compare each PE with the industry PE (36.42) and ask whether the growth rate justifies any gap.
3. Track domestic branded sales growth, export revenue, research spending and the operating margin.
4. Stagger entries across quarters and review institutional holding every reporting season.

Download the Univest iOS App or Univest Android App to track Sun Pharma, Torrent Pharma and Zydus Lifesciences live prices.

Conclusion

Among pharma stocks, Sun Pharma stands out for the fastest profit growth, 35.75% a year since FY22, Torrent Pharma for the highest return on equity at 25.49% and Zydus Lifesciences for the lowest PE of the group at 24.78. Which one suits a portfolio depends on how much valuation risk it can carry, so staggering entries and reviewing each quarterly result is a sound habit. Investors comparing pharma stocks should rank them on growth, financial strength and the price paid, and anyone who wants personalised guidance can consult a SEBI-registered advisor before acting.

Frequently Asked Questions on Pharma Stocks to Watch

Which are the best pharma stocks to watch for multibagger potential?

Ans. Sun Pharma, Torrent Pharma and Zydus Lifesciences are the 3 names this list highlights, with market caps of Rs 4,22,427 crore, Rs 1,75,196 crore and Rs 1,13,790 crore respectively. Sun Pharma is notable for the fastest profit growth, 35.75% a year since FY22. Torrent Pharma stands out for the highest return on equity at 25.49%. Zydus Lifesciences offers the lowest PE of the group at 24.78. These are watchlist names for pharma stocks, not recommendations, so match each one to your own risk profile and time horizon.

Is Torrent Pharma a good stock for long-term investors?

Ans. Torrent Pharma has a return on equity of 25.49%, a PE of 81.26 against an industry PE of 36.42 and a market cap of Rs 1,75,196 crore. Net profit has compounded at 28.79% a year since FY22, and FY26 revenue rose 20.34% while June 2026 quarter net profit grew 3.28%. Long-term returns in pharma stocks depend on earnings growth and the price paid at entry, so staggering purchases and consulting a SEBI-registered advisor is sensible.

Can Sun Pharma become a multibagger from here?

Ans. Sun Pharma has already gained 110.81% in five years, so another multi-fold move would need sustained earnings growth. A multibagger outcome in pharma stocks requires earnings to keep growing faster than the market for several years. Net profit has compounded at 35.75% a year since FY22, and FY26 revenue rose 12.69%. At a PE of 34.86 against an industry PE of 36.42, valuation should be checked against that growth before investing.

What is the market cap of Sun Pharma, Torrent Pharma and Zydus Lifesciences?

Ans. As of 16 October 2026, Sun Pharma has a market cap of Rs 4,22,427 crore, Torrent Pharma has a market cap of Rs 1,75,196 crore and Zydus Lifesciences has a market cap of Rs 1,13,790 crore. All of them qualify as largecaps. Market cap changes daily with the share price, so check the latest figure on the Univest Screener or on NSE before taking a decision on pharma stocks.

What are the risks of investing in pharma stocks?

Ans. The main risks are regulatory actions, pricing in export markets and valuation. A warning letter or delayed approval can affect launches, and some pharma stocks trade at premium PE ratios. Companies with diverse products and markets are better placed. Torrent Pharma trades at a PE of 81.26 against an industry PE of 36.42, so earnings growth needs to hold up.

Why is Torrent Pharma trading at a PE of 81.26?

Ans. Torrent Pharma's PE of 81.26 compares with an industry PE of 36.42. The market is paying a premium for a return on equity of 25.49%, profit growth of 28.79% a year since FY22 and FY26 revenue growth of 20.34%, which also means the stock is more sensitive if growth slows. Investors in pharma stocks who are comfortable with higher valuation risk may prefer to stagger purchases instead of investing in one go.

How much do institutions hold in Sun Pharma, Torrent Pharma and Zydus Lifesciences?

Ans. As of the latest reported quarter, FII and DII together hold 36.63% of Sun Pharma (14.36% and 22.27%), 30.84% of Torrent Pharma (17.97% and 12.87%) and 18.32% of Zydus Lifesciences (7.04% and 11.28%). Rising institutional holding is a useful signal in pharma stocks, though it should be read with earnings trends rather than on its own.